In pregnant patients with opioid use disorder (OUD), which pharmacotherapy is recommended: fentanyl, bupropion, naltrexone, buprenorphine, or methadone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Pharmacotherapy for Opioid Use Disorder in Pregnancy

Both buprenorphine and methadone are the only recommended pharmacotherapies for pregnant people with opioid use disorder—fentanyl, bupropion, and naltrexone are NOT appropriate treatments in this population. 1

Primary Treatment Options

First-Line Choices: Buprenorphine vs Methadone

Both medications are safe, effective, and represent the gold standard of care 1, 2, 3. However, buprenorphine demonstrates superior neonatal outcomes compared to methadone:

Neonatal outcomes favoring buprenorphine 1, 4:

  • 73% reduction in neonatal abstinence syndrome (NAS) risk (52.0% vs 69.2%) 4
  • Less medication required to treat NAS when it occurs
  • Shorter hospital stays (10.0 vs 17.5 days)
  • Shorter duration of NAS treatment (4.1 vs 9.9 days)
  • Higher birth weights (170g difference)
  • Lower rates of preterm birth (14.4% vs 24.9%)
  • Lower rates of small-for-gestational-age infants (12.1% vs 15.3%)

Maternal outcomes are equivalent between both medications 1, 4:

  • Similar relapse rates
  • Similar cesarean delivery rates
  • Similar rates of serious maternal complications (3.3% vs 3.5%)
  • Methadone shows higher treatment retention/completion rates

Clinical Decision Algorithm

Choose buprenorphine when 1:

  • Patient has good past response to buprenorphine
  • Buprenorphine prescriber is available and accessible
  • Patient had inadequate response to methadone
  • This should be the default choice given superior neonatal outcomes

Choose methadone when 1:

  • Concurrent benzodiazepine or CNS depressant use (though buprenorphine should NOT be withheld if it's the only accessible option—use careful medication management per FDA) 1
  • Patient unable to tolerate buprenorphine
  • Buprenorphine proven ineffective
  • High-potency synthetic opioid use (fentanyl) where methadone may provide better stabilization 5, 6

Medications That Are NOT Recommended

Fentanyl: This is an opioid agonist used for analgesia, NOT for OUD treatment. It has no role in managing opioid use disorder in pregnancy 7.

Bupropion: This is an antidepressant with no efficacy for OUD and is not mentioned in any pregnancy OUD treatment guidelines.

Naltrexone: While FDA-approved for OUD, insufficient data exist to recommend its use in pregnancy 1. The evidence shows:

  • Only retrospective and small prospective studies available 8
  • Requires complete opioid detoxification before initiation
  • High relapse risk during the detoxification period
  • Rapid clearance creates vulnerability to relapse if discontinued
  • Cannot be used in opioid-dependent patients
  • Not recommended as standard treatment option 1

Practical Implementation Details

Buprenorphine Dosing 1

  • Standard daily dose: 16 mg (range 4-24 mg)
  • Pregnancy may require higher and more frequent dosing (2-4 times daily)
  • Dosing needs increase with advancing gestational age
  • Buprenorphine-naloxone combination (Suboxone) can be continued if patient becomes pregnant while on it—theoretical concerns about naloxone component are not supported by data 1

Buprenorphine Induction 1

  • Requires mild opioid withdrawal symptoms before initiation
  • Abstain from short-acting opioids 12-24 hours
  • Abstain from long-acting opioids 36-48 hours
  • Verify withdrawal with validated scale
  • Initial dose followed by reassessment in 30 minutes
  • Can give additional 2-4 mg if tolerated

Methadone Considerations 3, 6

  • Pregnancy increases clearance and decreases half-life
  • May require dose increases or more frequent dosing intervals
  • More pharmacokinetic data needed during pregnancy
  • Switching from methadone to buprenorphine is challenging due to withdrawal risk

Critical Safety Information

Both medications are NOT associated with 1:

  • Increased birth defects
  • Long-term neurodevelopmental harm (when comparing similar socioeconomic groups)

Common expected effects 1:

  • Neonatal Opioid Withdrawal Syndrome (NOWS) occurs with both medications
  • Reduced fetal activity and heart rate
  • Fetal growth restriction

Common Pitfalls to Avoid

  1. Do NOT withhold buprenorphine from patients using benzodiazepines if it's the only accessible option 1
  2. Do NOT attempt medication-assisted withdrawal/detoxification—relapse rates are extremely high and risks are unquantified 1
  3. Do NOT use naltrexone as standard treatment—insufficient pregnancy data 1
  4. Do NOT underdose—pregnancy increases metabolism of both medications 2, 3, 6
  5. Do NOT forget postpartum planning—establish continuation plans during pregnancy as postpartum is high-risk period for relapse and overdose 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.